Miao D, Margolis CA, Vokes NI, et al. Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors. Nat Genet. 2018;50(9):1271-1281. doi:10.1038/s41588-018-0200-2
Kong SW, Lee IH, Liu X, Hirschhorn JN, Mandl KD. Measuring coverage and accuracy of whole-exome sequencing in clinical context. Genet Med. 2018;20(12):1617-1626. doi:10.1038/gim.2018.51
Merkle FT, Ghosh S, Kamitaki N, et al. Human pluripotent stem cells recurrently acquire and expand dominant negative P53 mutations. Nature. 2017;545(7653):229-233. doi:10.1038/nature22312
Balasubramanian S, Fu Y, Pawashe M, et al. Using ALoFT to determine the impact of putative loss-of-function variants in protein-coding genes. Nat Commun. 2017;8(1):382. doi:10.1038/s41467-017-00443-5
Bihlmeyer NA, Brody JA, Smith AV, et al. ExomeChip-Wide Analysis of 95 626 Individuals Identifies 10 Novel Loci Associated With QT and JT Intervals. Circ Genom Precis Med. 2018;11(1):e001758. doi:10.1161/CIRCGEN.117.001758
Boycott KM, Rath A, Chong JX, et al. International Cooperation to Enable the Diagnosis of All Rare Genetic Diseases. Am J Hum Genet. 2017;100(5):695-705. doi:10.1016/j.ajhg.2017.04.003
Cassa CA, Weghorn D, Balick DJ, et al. Reply to ’Selective effects of heterozygous protein-truncating variants’. Nat Genet. 2019;51(1):3-4. doi:10.1038/s41588-018-0301-y
Rheinbay E, Parasuraman P, Grimsby J, et al. Recurrent and functional regulatory mutations in breast cancer. Nature. 2017;547(7661):55-60. doi:10.1038/nature22992
Heyne HO, Singh T, Stamberger H, et al. De novo variants in neurodevelopmental disorders with epilepsy. Nat Genet. 2018;50(7):1048-1053. doi:10.1038/s41588-018-0143-7
Whiffin N, Minikel E, Walsh R, et al. Using high-resolution variant frequencies to empower clinical genome interpretation. Genet Med. 2017;19(10):1151-1158. doi:10.1038/gim.2017.26